S&P 500   4,443.11
DOW   34,869.37
QQQ   370.35
pixel
pixel
S&P 500   4,443.11
DOW   34,869.37
QQQ   370.35
pixel
pixel
S&P 500   4,443.11
DOW   34,869.37
QQQ   370.35
pixel
pixel
S&P 500   4,443.11
DOW   34,869.37
QQQ   370.35
pixel
pixel
NASDAQ:PYPD

PolyPid Stock Forecast, Price & News

$7.78
-0.26 (-3.23 %)
(As of 09/27/2021 12:00 AM ET)
Add
Compare
Today's Range
$7.65
$8.05
50-Day Range
$7.14
$9.48
52-Week Range
$6.95
$16.50
Volume18,054 shs
Average Volume48,629 shs
Market Capitalization$132.62 million
P/E RatioN/A
Dividend YieldN/A
Beta0.3
30 days | 90 days | 365 days | Advanced Chart
Receive PYPD News and Ratings via Email

Sign-up to receive the latest news and ratings for PolyPid and its competitors with MarketBeat's FREE daily newsletter.


PolyPid logo

About PolyPid

PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product includes D-PLEX100, which is in Phase 3 clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PYPD
CIK
N/A
Employees
67
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$4.27 per share

Profitability

Net Income
$-36,870,000.00

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$132.62 million
Next Earnings Date
11/10/2021 (Estimated)
Optionable
Not Optionable

MarketRank

Overall MarketRank

1.86 out of 5 stars

Medical Sector

718th out of 1,353 stocks

Surgical & Medical Instruments Industry

72nd out of 123 stocks

Analyst Opinion: 3.7Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












PolyPid (NASDAQ:PYPD) Frequently Asked Questions

Is PolyPid a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for PolyPid in the last year. There are currently 2 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" PolyPid stock.
View analyst ratings for PolyPid
or view top-rated stocks.

What stocks does MarketBeat like better than PolyPid?

Wall Street analysts have given PolyPid a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but PolyPid wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting PolyPid?

PolyPid saw a decrease in short interest during the month of August. As of August 31st, there was short interest totaling 21,200 shares, a decrease of 33.8% from the August 15th total of 32,000 shares. Based on an average trading volume of 26,700 shares, the days-to-cover ratio is presently 0.8 days. Currently, 0.2% of the shares of the company are short sold.
View PolyPid's Short Interest
.

When is PolyPid's next earnings date?

PolyPid is scheduled to release its next quarterly earnings announcement on Wednesday, November 10th 2021.
View our earnings forecast for PolyPid
.

How were PolyPid's earnings last quarter?

PolyPid Ltd. (NASDAQ:PYPD) posted its quarterly earnings results on Wednesday, August, 11th. The company reported ($0.56) earnings per share for the quarter, missing analysts' consensus estimates of ($0.54) by $0.02.
View PolyPid's earnings history
.

What price target have analysts set for PYPD?

3 brokers have issued 12-month price targets for PolyPid's shares. Their forecasts range from $14.00 to $24.00. On average, they anticipate PolyPid's share price to reach $19.00 in the next year. This suggests a possible upside of 144.2% from the stock's current price.
View analysts' price targets for PolyPid
or view top-rated stocks among Wall Street analysts.

Who are PolyPid's key executives?

PolyPid's management team includes the following people:
  • Mr. Amir Weisberg, CEO & Director (Age 65, Pay $936.62k)
  • Ms. Dikla Czaczkes Akselbrad, Exec. VP & CFO (Age 48, Pay $565.17k)
  • Dr. Noam Emanuel, Chief Scientific Officer (Age 62, Pay $804.82k)
  • Ms. Dalit Hazan, VP of R&D and Regulatory Affairs (Age 50, Pay $232.95k)
  • Dr. Shaul Mukhtar Ph.D., Exec. VP & COO (Age 65)
  • Mr. Ori Warshavsky, VP of Marketing
  • Ms. Moran Cohen, Site Mang.

What other stocks do shareholders of PolyPid own?

When did PolyPid IPO?

(PYPD) raised $50 million in an IPO on Friday, June 26th 2020. The company issued 3,100,000 shares at $15.00-$17.00 per share. Barclays and BMO Capital Markets served as the underwriters for the IPO and Raymond James, National Securities Corporation, Oddo BHF and A.G.P. were co-managers.

What is PolyPid's stock symbol?

PolyPid trades on the NASDAQ under the ticker symbol "PYPD."

Who are PolyPid's major shareholders?

PolyPid's stock is owned by many different retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (3.55%), Victory Capital Management Inc. (0.65%), Millennium Management LLC (0.33%), Invesco Ltd. (0.14%), Renaissance Technologies LLC (0.11%) and Federated Hermes Inc. (0.11%).

Which institutional investors are selling PolyPid stock?

PYPD stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., Federated Hermes Inc., and Victory Capital Management Inc..

Which institutional investors are buying PolyPid stock?

PYPD stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, ARK Investment Management LLC, Renaissance Technologies LLC, Meitav Dash Investments Ltd., Meitav Dash Investments Ltd., Cresset Asset Management LLC, Geode Capital Management LLC, and Morgan Stanley.

How do I buy shares of PolyPid?

Shares of PYPD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PolyPid's stock price today?

One share of PYPD stock can currently be purchased for approximately $7.78.

How much money does PolyPid make?

PolyPid has a market capitalization of $132.62 million. The company earns $-36,870,000.00 in net income (profit) each year or ($4.07) on an earnings per share basis.

How many employees does PolyPid have?

PolyPid employs 67 workers across the globe.

What is PolyPid's official website?

The official website for PolyPid is www.polypid.com.

Where are PolyPid's headquarters?

How can I contact PolyPid?

PolyPid's mailing address is 18 HASIVIM STREET P.O BOX 7126, PETACH TIKVA L3, 4959376. The company can be reached via phone at 908-378-9530.


This page was last updated on 9/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.